Compared to DNA sequencing alone, concurrent DNA and RNA sequencing revealed more clinically actionable variants in NSCLC.

Orna Therapeutics, part of a buzzy cohort of biotech companies established in the wake of the Covid pandemic, has cut more ...

BioNTech said that it is acquiring the Chinese drugmaker Biotheus for $800 million to bolster its cancer strategy. The two ...

An RNA-editing gene therapy has been developed that switches off the key driver of common eye conditions affecting diabetics ...

The firm has made significant strides in its RNA editing and RNA interference programs, which are attracting positive attention and positioning the company for differentiation in the treatment of ...

Multiple myeloma (MM) is an incurable blood cancer, leading to weakened immunity, bone damage, and other serious health ...

Genes contain instructions for making proteins, and a central dogma of biology is that this information flows from DNA to RNA ...

TD Cowen analyst Ritu Baral maintained a Buy rating on Avidity Biosciences (RNA – Research Report) today and set a price target of $78.00. The company’s shares closed yesterday at $46.73. Baral covers ...

Nearly three decades later, drug makers have developed six approved small interfering RNA (siRNA) therapeutics in the ...

Avidity Biosciences stock surges on expansion of pipeline targeting rare genetic cardiomyopathies and improvements in siRNA ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care ...